KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesSales of Property, Plant and EquipmentShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Amneal Pharmaceuticals (AMRX) Other financing activities (2017 - 2025)

Historic Other financing activities for Amneal Pharmaceuticals (AMRX) over the last 6 years, with Q3 2025 value amounting to $73.2 million.

  • Amneal Pharmaceuticals' Other financing activities changed N/A to $73.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was $235.6 million, marking a year-over-year increase of 4508.7%. This contributed to the annual value of $162.4 million for FY2023, which is 966638.6% up from last year.
  • As of Q3 2025, Amneal Pharmaceuticals' Other financing activities stood at $73.2 million.
  • Amneal Pharmaceuticals' Other financing activities' 5-year high stood at $161.9 million during Q4 2023, with a 5-year trough of $41000.0 in Q3 2022.
  • Over the past 3 years, Amneal Pharmaceuticals' median Other financing activities value was $36.9 million (recorded in 2023), while the average stood at $58.9 million.
  • The largest annual percentage gain for Amneal Pharmaceuticals' Other financing activities in the last 5 years was 122195.12% (2023), contrasted with its biggest fall of 122195.12% (2023).
  • Quarter analysis of 3 years shows Amneal Pharmaceuticals' Other financing activities stood at $41000.0 in 2022, then soared by 394712.2% to $161.9 million in 2023, then tumbled by 54.76% to $73.2 million in 2025.
  • Its Other financing activities was $73.2 million in Q3 2025, compared to $161.9 million in Q4 2023 and $542000.0 in Q3 2023.